Srour Nadim, Chaparro Cecilia, Vandemheen Katherine, Singer Lianne G, Keshavjee Shaf, Aaron Shawn D
Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Québec, Canada; Faculty of Medicine, McGill University, Montréal, Québec, Canada; Division of Pulmonology, Department of Medicine, Hôpital Charles-LeMoyne, Greenfield Park, Québec, Canada; Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Mount Sinai Hospital Centre, Montréal, Québec, Canada.
Toronto Lung Transplant Program, University of Toronto, University Health Network, Toronto, Ontario, Canada; Adult Cystic Fibrosis Clinic St. Michael's Hospital, Toronto, Ontario, Canada.
J Heart Lung Transplant. 2015 Apr;34(4):588-93. doi: 10.1016/j.healun.2014.09.040. Epub 2014 Oct 2.
Compared with patients infected with unique strains of Pseudomonas aeruginosa, patients with cystic fibrosis who are infected with transmissible strains of P aeruginosa, such as the Liverpool epidemic strain, have a 3-fold greater risk of death or lung transplant. We aimed to determine if pre-operative infection with transmissible strains of P aeruginosa was similarly associated with poor health outcomes after lung transplant.
We had prospectively identified and characterized endobronchial infections in 446 adult cystic fibrosis patients in Ontario, Canada, from September 2005 until December 2009. P aeruginosa isolated from sputum taken at 3-month intervals was genotyped, and patients were characterized as being infected with 1 of 2 transmissible strains or, alternatively, with unique strains of P aeruginosa. We monitored patients until 2013 and collected data on patients from the cohort who subsequently received a lung transplant. The primary outcome was survival after transplantation.
We identified 56 lung transplant recipients from the cohort of 446 patients, including 18 infected with transmissible strains of P aeruginosa and 26 infected with unique P aeruginosa strains. Post-transplant survival at 3 years was 86% in the transmissible group and 84% in the unique group (p = 0.65). No significant differences between groups were found regarding bronchiolitis obliterans-free survival, the frequency of acute rejection episodes, the frequency of post-transplant respiratory tract infection, or the rate of change of post-transplant forced expiratory volume in 1 second.
Pre-operative infection with transmissible strains of P aeruginosa is not associated with poorer post-transplant outcomes compared with patients infected with unique strains of P aeruginosa.
与感染铜绿假单胞菌独特菌株的患者相比,感染可传播菌株(如利物浦流行菌株)的囊性纤维化患者死亡或肺移植风险高3倍。我们旨在确定术前感染铜绿假单胞菌可传播菌株是否同样与肺移植后不良健康结局相关。
2005年9月至2009年12月,我们前瞻性地识别并描述了加拿大安大略省446例成年囊性纤维化患者的支气管内感染情况。对每隔3个月采集的痰液中分离出的铜绿假单胞菌进行基因分型,患者被分为感染2种可传播菌株之一或感染铜绿假单胞菌独特菌株。我们对患者进行随访至2013年,并收集该队列中随后接受肺移植患者的数据。主要结局是移植后的生存率。
我们在446例患者队列中识别出56例肺移植受者,其中18例感染铜绿假单胞菌可传播菌株,26例感染铜绿假单胞菌独特菌株。可传播菌株组3年移植后生存率为86%,独特菌株组为84%(p = 0.65)。在无闭塞性细支气管炎生存率、急性排斥反应发作频率、移植后呼吸道感染频率或移植后第1秒用力呼气量变化率方面,两组之间未发现显著差异。
与感染铜绿假单胞菌独特菌株的患者相比,术前感染铜绿假单胞菌可传播菌株与移植后较差结局无关。